- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 12.08. | Xilio Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 3 | SEC Filings | ||
| 12.08. | Xilio Therapeutics GAAP EPS of -$0.33, revenue of $18.7M | 2 | Seeking Alpha | ||
| XILIO THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 12.08. | Xilio Therapeutics, Inc. - 10-Q, Quarterly Report | 2 | SEC Filings | ||
| 12.08. | Xilio Therapeutics, Inc.: Xilio Therapeutics Reports Second Quarter 2026 Financial Results and Provides Pipeline and Business Updates | 260 | GlobeNewswire (Europe) | Received FDA clearance of IND application for XTX501, a potential best-in-class bispecific PD-1 / masked IL-2 Advancing IND-enabling studies for potential first-in-class multi-specific, masked T cell... ► Artikel lesen | |
| 12.08. | Xilio Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 06.07. | Xilio Therapeutics, Inc.: Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 1 | GlobeNewswire (USA) | ||
| 29.06. | Xilio Therapeutics beruft Ben Harshbarger zum neuen Chief Legal Officer | 3 | Investing.com Deutsch | ||
| 29.06. | Xilio Therapeutics appoints Ben Harshbarger as chief legal officer | 4 | Investing.com | ||
| 29.06. | Xilio Therapeutics, Inc.: Xilio Therapeutics Appoints Ben Harshbarger as Chief Legal Officer | 690 | GlobeNewswire (Europe) | WALTHAM, Mass., June 29, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people... ► Artikel lesen | |
| 12.06. | Xilio Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 12.05. | Xilio Therapeutics reports Q1 results | 1 | Seeking Alpha | ||
| 12.05. | Xilio Therapeutics, Inc.: Xilio Therapeutics Reports First Quarter 2026 Financial Results and Provides Pipeline and Business Updates | 583 | GlobeNewswire (Europe) | On track for planned IND submission in mid-2026 and Phase 1 initiation in the second half of 2026 for XTX501, a potential best-in-class bispecific PD-1 / masked IL-2 Presented new preclinical data... ► Artikel lesen | |
| 12.05. | Xilio Therapeutics, Inc. - 10-Q, Quarterly Report | 2 | SEC Filings | ||
| 12.05. | Xilio Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 07.05. | Xilio Therapeutics, Inc.: Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 1 | GlobeNewswire (USA) | ||
| 17.04. | Xilio Therapeutics, Inc.: Xilio Therapeutics Announces New Preclinical Data at AACR Annual Meeting for XTX601, a Masked T Cell Engager Targeting CLDN18.2 | 1 | GlobeNewswire (USA) | ||
| 16.04. | Xilio Therapeutics appoints Cheryl Blanchard to board | 1 | Investing.com | ||
| 16.04. | Xilio Therapeutics, Inc.: Xilio Therapeutics Appoints Cheryl R. Blanchard, Ph.D. to its Board of Directors | 1 | GlobeNewswire (USA) | ||
| 16.04. | Xilio Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 03.04. | Xilio Therapeutics, Inc.: Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 2 | GlobeNewswire (USA) |
1 2 Weiter >>
38 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| VALNEVA | 2,945 | -0,14 % | Original-Research: Valneva SE (von First Berlin Equity Research GmbH): Buy | Original-Research: Valneva SE - von First Berlin Equity Research GmbH
21.08.2026 / 10:04 CET/CEST
Veröffentlichung einer Research, übermittelt durch EQS News - ein Service der EQS Group.
Für den... ► Artikel lesen | |
| VIVORYON THERAPEUTICS | 1,120 | -0,88 % | Vivoryon Therapeutics N.V. to Hold its 2026 Annual General Meeting on September 29, 2026 | Vivoryon Therapeutics N.V. to Hold its 2026 Annual General Meeting on September 29, 2026
Halle (Saale) / Munich, Germany, August 18, 2026 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7)... ► Artikel lesen | |
| SAREPTA THERAPEUTICS | 16,660 | +3,48 % | Biotech-Player: Zelltherapie als Comeback-Story im Milliardenmarkt. Neue Ideen nach Corona von BioNTech, Qiagen und Biotech AG | ||
| TRAWS PHARMA | 0,530 | 0,00 % | Traws Pharma Ties Up To $50 Million Of Additional Financing To Influenza Regulatory And Clinical Milestones | ||
| VERASTEM | 5,758 | -2,47 % | Mizuho lowers Verastem stock price target on valuation to $13 | ||
| TRINITY BIOTECH | 10,490 | 0,00 % | TRINITY BIOTECH PLC - F-1/A, Registration statement for certain foreign private issuers | ||
| ZAI LAB LTD ADR | 22,400 | 0,00 % | Zai Lab Limited: Zai Lab and argenx Announce Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis | Study met primary endpoint of mean Total Improvement Score (TIS) at Week 52 in the combined study population of IMNM and DM patients (p=0.0011) Patient improvements observed early and sustained... ► Artikel lesen | |
| VOYAGER THERAPEUTICS | 2,864 | -0,90 % | Voyager Therapeutics, Inc.: Voyager Demonstrates Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 6-Month GLP Toxicology Study; Initiation of Clinical Trial in Alzheimer's Disease Expected H2 2026 | - Data presented as Developing Topics poster at AAIC 2026 - LEXINGTON, Mass., July 13, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging... ► Artikel lesen | |
| TVARDI THERAPEUTICS | 1,610 | +1,26 % | Tvardi Therapeutics Announces Second Quarter 2026 Results and Provides Business Update | Reported topline healthy volunteer results for next-generation STAT3 inhibitor TTI-109, confirming the prodrug design, improved tolerability and reductions in disease-relevant immune cell populations... ► Artikel lesen | |
| XBIOTECH | 1,912 | 0,00 % | XBiotech Inc.: XBiotech startet klinische Phase-II-Studie zur Bewertung von Vilamakitug bei der Behandlung der aktiven axialen Spondyloarthritis | Der IND-Antrag für die V-SPINE-Studie hat die 30-tägige FDA-Prüfung ohne klinischen Stopp durchlaufen und ebnet damit den Weg für die Aufnahme von Patienten in den USAAUSTIN, Texas, June 15, 2026 (GLOBE... ► Artikel lesen | |
| VANDA PHARMACEUTICALS | 4,500 | -0,57 % | Vanda Pharmaceuticals Inc.: Vanda Pharmaceuticals Reports Second Quarter 2026 Financial Results | Fanapt® Q2 2026 net product sales increased 23% to $36.0 million; total prescriptions increased 31%
Full-year 2026 total revenue guidance of $240-$290 million... ► Artikel lesen | |
| ZEVRA THERAPEUTICS | 10,450 | +2,96 % | Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | ||
| SPERO THERAPEUTICS | 1,043 | -0,57 % | Spero Therapeutics, Inc.: Spero Therapeutics Announces Second Quarter 2026 Operating Results and Provides Business Update | Entered an exclusive license agreement with Innovent Biologics for SP001, a Phase 2-ready, third-generation anti-CD40L antibody for immune-mediated diseases U.S. Food and Drug Administration approved... ► Artikel lesen | |
| TENAX THERAPEUTICS | 1,540 | +2,67 % | Orion Oyj: Orion's license partner Tenax Therapeutics' Phase 3 LEVEL trial of oral levosimendan in pulmonary hypertension due to heart failure with preserved ejection fraction (PH-HFpEF) did not reach its primary endpoint | ORION CORPORATION STOCK EXCHANGE RELEASE - INSIDE INFORMATION 10 AUGUST 2026 at 14.05 EEST Orion's license partner Tenax Therapeutics' Phase 3 LEVEL trial of oral levosimendan in pulmonary... ► Artikel lesen | |
| VIR BIOTECHNOLOGY | 9,795 | +0,15 % | Vir Biotechnology, Inc.: Vir Biotechnology to Present Complete Week 96 Data from Phase 2 SOLSTICE Clinical Trial in Hepatitis Delta at the European Association for the Study of the Liver (EASL) Congress 2026 | - Oral presentation of complete Week 96 data from the Phase 2 SOLSTICE trial in chronic hepatitis delta selected for inclusion in "Best of EASL 2026" by EASL - Poster presentation of Week 48... ► Artikel lesen |
Das Unternehmen XILIO THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell -1,30 % bei einem Aktienkurs von 9,110 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu XILIO THERAPEUTICS INC finden Sie auf Wallstreet Online.